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Abstract
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen component of Ayahuasca, an
Amazonian beverage traditionally used for ritual, religious and healing purposes that is being increasingly
used for recreational purposes in US and Europe. 5MeO-DMT is of potential interest for schizophrenia research
owing to its hallucinogenic properties. Two other psychotomimetic agents, phencyclidine and 2,5-dimethoxy-4-
iodo-phenylisopropylamine (DOI), markedly disrupt neuronal activity and reduce the power of low frequency
cortical oscillations (<4 Hz, LFCO) in rodent medial prefrontal cortex (mPFC). Here we examined the effect of
5-MeO-DMT on cortical function and its potential reversal by antipsychotic drugs. Moreover, regional brain
activity was assessed by blood-oxygen level dependent (BOLD) functional magnetic resonance imaging
(fMRI). 5-MeO-DMT disrupted mPFC activity, increasing and decreasing the discharge of 51 and 35% of the
recorded pyramidal neurons, and reducing (−31%) the power of LFCO. The latter effect depended on 5-HT1A
and 5-HT2A receptor activation and was reversed by haloperidol, clozapine, risperidone, and the mGlu2/3 ago-
nist LY379268. Likewise, 5-MeO-DMT decreased BOLD responses in visual cortex (V1) and mPFC. The disrup-
tion of cortical activity induced by 5-MeO-DMT resembles that produced by phencyclidine and DOI. This,
together with the reversal by antipsychotic drugs, suggests that the observed cortical alterations are related to
the psychotomimetic action of 5-MeO-DMT. Overall, the present model may help to understand the neurobiolo-
gical basis of hallucinations and to identify new targets in antipsychotic drug development.
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Introduction
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is
a psychoactive compound found in Ayahuasca, an hal-
lucinogenic beverage used in ritual ceremonies and for
healing purposes (McKenna et al., 1984; Schultes and
Hofmann, 1991; McKenna, 2004). Ayahuasca is being
investigated for its potential clinical uses (McKenna,
2004). Its psychedelic effects include visual and auditory
stimulation, mixing of sensory modalities, and deep psy-
chological introspection. In addition to the methylated
indolamines, Ayahuasca contains β-carbolines, reversible
inhibitors of monoamine oxidase-A (MAO-A), which pre-
vent indolemaine deamination and increase their blood
concentration and their psychedelic action (Agurell
et al., 1968; McKenna et al., 1984).
Several 5-HT2A receptor (5-HT2A-R) agonists, including
5-MeO-DMT, lysergic acid diethylamide (LSD), 2,5-
dimethoxy-4-iodo-phenylisopropylamine (DOI), mesc-
aline and psilocybin possess hallucinogenic properties,
altering perception, emotion and mood (Glennon, 1991,
1994; Nichols, 2004). The interest of psychedelic agents
lies in their capacity to model certain aspects of psychosis
in experimental research (Geyer and Vollenweider, 2008),
helping also to identify brain areas/circuits altered in psy-
chiatric disorders (Vollenweider et al., 1997a, b). Further,
some of them may be useful in the treatment of psychi-
atric disorders (Vollenweider and Kometer, 2010).
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Interestingly, not all 5-HT2A-R agonists are hallucinogens,
raising questions about the neural mechanisms respon-
sible for their properties. Thus, differences in signaling
pathways have been suggested (Kurrasch-Orbaugh et al.,
2003; Gonzalez-Maeso et al., 2007).
5-MeO-DMT is synthesized and distributed for recrea-
tional purposes (Yu, 2008) and intoxications have been
reported (Brush et al., 2004; Sklerov et al., 2005). Early
reports suggested 5-MeO-DMT as a possible endogenous
psychotoxin and several studies indicated its potential in-
volvement in schizophrenia (Benington et al., 1965;
Angrist et al., 1976; Gillin and Wyatt, 1976). In 2010 the
Deputy Administrator of the Drug Enforcement Adminis-
tration (DEA) placed 5-MeO-DMT into schedule I of the
Controlled Substances Act (Drug Enforcement Adminis-
tration (DEA), 2010).
The non-competitive N-methyl-D-aspartate receptor
(NMDA) receptor antagonist phencyclidine (PCP)
(Kargieman et al., 2007, 2012) and the preferential
5-HT2A-R agonist DOI (Celada et al., 2008), markedly dis-
rupt cortical function in rodents. increasing pyramidal
neuron discharge and reducing low frequency cortical
oscillations (LFCO) in medial prefrontal cortex (mPFC)
(see (Celada et al., 2013) for review). Here we examined
the effects of 5-MeO-DMT on cortical function in rats,
and the potential reversal of these actions by antipsycho-
tic drugs. Likewise, 5-MeO-DMT effects on regional
brain activity were examined using functional magnetic
resonance imaging (fMRI). The main objective of the
study was to gain further insight into the neurobiological
basis of hallucinations, helping also to identify new tar-
gets in schizophrenia treatment.
Materials and methods
Animals
Male albino Wistar rats (250–320 g) were used (Iffa Credo,
France). Animal care followed the European Union regu-
lations (O.J. of E.C. L358/1 18/12/1986) and was approved
by the Institutional Animal Care and Use Committee.
Drugs and treatments
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT),
WAY-100635, clozapine (CLZ), risperidone (RIS) and
clorgyline hydrochloride (CLG) were from Sigma/RBI
(USA). M100907 [R-(+)-alpha-(2,3-dimethoxyphenil)-1-[4-
ﬂuorophenylethyl]-4-piperidinemethanol] was a gift of
Pierre Fabre Médicament (France), haloperidol (HAL)
was from Laboratorios Esteve (Spain) and LY-379268
{(–)-2-oxa-4-aminobicyclo-[3.1.0]hexane-4,6-dicarboxylate]}
was from Tocris (UK).
All experiments were done in chloral hydrate anesthe-
tized rats (400mg/kg i.p. followed by 50–70mg/kg/h
using a perfusion pump). Drugs were administered intra-
venously (i.v) at the doses stated. To mimic Ayahuasca
effects, preventing a rapid peripheral deamination of
5-MeO-DMT by MAO-A in lungs and liver, rats were pre-
treated with the selective MAO-A inhibitor clorgyline
(0.3 mg/kg) 15min prior 5-MeO-DMT administration
(Halberstadt et al., 2008). Seven groups of rats were ad-
ministered with 5-MeO-DMT (0.1 mg/kg in all instances)
followed by (a) saline, (b) CLZ (1mg/kg), (c) HAL (0.1–
0.2 mg/kg), (d) RIS (0.2 mg/kg), (e) WAY100635 (50–
100 μg/kg), (f) M100907 (0.3 mg/kg), and (g) LY-379268
(0.5–2mg/kg). Time between injections was 5min.
To assess the effect of 5-HT1A-R antagonist
WAY100635, 5-HT2A-R antagonist M100907 and
mGluR2/3 agonist LY-379268 on LFCO we administrated
intravenously cumulative doses (25–100 μg/kg), (0.15–
0.6 mg/kg) and (0.5–2mg/kg) of WAY100635, M100907
and LY-379268, respectively.
Electrophysiology: single unit and LFP recordings
Electrophysiological procedures were performed essen-
tially as described elsewhere (Kargieman et al., 2007).
Recordings of pyramidal neurons and oscillatory activity
local ﬁeld potential (LFP) were carried out in the mPFC
(AP+3.2 to +3.4, L−0.2 to −0.5, DV −1.0 to −4; coordi-
nates in mm (Paxinos and Watson, 2005)). All recorded
pyramidal neurons were identiﬁed by antidromic acti-
vation from ventral tegmental area and collision test
(Fuller and Schlag, 1976). In some experiments simul-
taneous recordings of oscillatory activity in the primary
visual area (V1, AP−7.5, L−3.5) were performed using
epidural electrodes.
After recording stable baseline activity for 5min,
clorgyline was slowly administered (30–45 s). 5-MeO-
DMT was injected 15min after clorgyline administration,
followed by antipsychotics or receptor ligands 5min later.
At the end of experiments, rats were killed by anesthetic
overdose. Brain sections were stained with Neutral Red,
according to standard procedures, to verify the recording
and stimulation sites.
fMRI protocol
fMRI experiments were conducted on a 7.0T BioSpec
70/30 horizontal animal scanner (Bruker BioSpin,
Germany), equipped with a 12-cm inner diameter actively
shielded gradient system (400mT/m). The receiver coil
was a phased array surface coil for the rat brain. fMRI
was achieved using blood oxygenation level-dependent
(BOLD) technique. Anesthesia was as in electrophysiolo-
gical experiments, and MRI acquisition started 20min
after CLG administration (0.3 mg/kg, i.v.). TurboRARE
images covering the whole brain were continuously
acquired during 50min (20min before and 30min after
5-MeO-DMT administration). Control animals received
CLG and saline and were equally scanned for 50min.
Scan parameters were: echo time (TE)=22ms, repetition
time (TR)=1600ms, 118 repetitions, ﬁeld of view (FOV)
=25×25×20mm, matrix size=64×64×20 pixels, resulting
in a spatial resolution of 0.39 in 1mm slice thickness.
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To examine the effect of 5-MeO-DMT on arterial
blood gas levels, the left femoral artery and vein were
cannulated. Arterial blood samples (0.15 ml) were taken
5min previous and 5, 10 15 and 20min after treatment
(saline or 5-MeO-DMT) administration. CLG (0.3 mg/kg
i.v.) was administered 20min before arterial blood
sample adquisition to mimic fMRI experimental
conditions.
Data analysis
Firing rate was quantiﬁed by averaging the values in
2-min periods in each experimental period (4th–5th min
after drug injection) and compared to pre-drug conditions
(baseline or 5-MeO-DMT). Neurons were considered
to be excited or inhibited when drugs induced a ±30%
change of the discharge rate (Kargieman et al., 2007).
Comparisons were made by determining the change for
each individual neuron and then coming up with the
mean of those percentages changes. Burst analysis was
carried out using previously described procedures
(Laviolette et al., 2005). Off-line analysis was performed
using the SPIKE 2 software (Cambridge Electronic De-
sign, Cambridge, UK). Drug effects on LFCO (0.15–
4 Hz) were analyzed, as follows. Power spectra were con-
structed (Fig. 1d) by using Fast Fourier Transformation
(FFT) of 1-min signal intervals (band-pass ﬁlter of 0.1–
100Hz). Power data of 2-min periods were averaged,
corresponding to baseline (4th–5th min), clorgyline
(14th–15th min post-administration), 5-MeO-DMT (4th–
5th min post-administration), and 5-MeO-DMT+drug
(4th–5th min post-administration of last drug). Power res-
olution was 0.15 Hz. Results are given as area under
curves (AUCs).
In MRI experiments, regions of interest (ROI; Fig. 2)
were drawn over the ﬁrst volume and signal intensity
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Fig. 1. Effect of 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) on pyramidal ﬁring rate and low frequency cortical oscillation
(LFCO) in rat medial prefrontal cortex (mPFC). (a and b) Examples of pyramidal neurons whose discharge was increased and
decreased, respectively, by 5-MeO-DMT administration. (c) Bar graph showing the average effect of 5-MeO-DMT on ﬁring rate
according to the type of response. EXC, excited neurons (n=19); INH, inhibited neurons (n=13); UN, unaffected neurons (n=5).
(D1) Spectrogram showing the effect of clorgyline and 5-MeO-DMT followed by saline on LFCO. Note the reduction in LFCO
power, denoted by the color change, after 5-MeO-DMT administration. The intensity of the power spectrum is color-coded (red=
high intensity; blue= low intensity). 5-MeO-DMT effect is long lasting (>10min in this example). (D2) local ﬁeld potential (LFP)
recordings (10 s each) at the times indicated in the spectrogram. (D3) The power spectra of the above recordings (1 min each,
around the above 10-s periods). Arrows mark drug injection. CLG: clorgyline hydrochloride.
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proﬁles were extracted for the next 117 volumes. After
curve smoothing, AUCs of 5-min intervals were analyzed
over a 25-min period corresponding to 5min prior saline
or 5-MeO-DMT administration and 20min after saline
or drug administration. Signal intensity changes after
saline or 5-MeO-DMT were expressed as percentage of
signal intensity change obtained in the 5min period be-
fore the injection.
All data were analyzed using one- or two-way
repeated-measures ANOVA (analysis of variance) fol-
lowed by Newman–Keuls post-hoc test or paired
Student’s t test, as appropriate. Statistical signiﬁcance
was set at the 95% conﬁdence level (two-tailed). Data
are given as mean±S.E.M.
Results
Effects of clorgyline pre-treatment on mPFC activity
Clorgyline administration did not alter the ﬁring rate
of pyramidal neurons in mPFC (from 0.6±0.1 to 0.7±
0.1 spike/s; n.s, paired Student’s t test; n=30, Fig. 1).
Likewise, the power of LFCO remained stable (0.31±
0.02 vs. 0.31±0.02 in basal and clorgyline periods; respect-
ively; n.s paired Student’s t test; n=60).
Effects of 5-MeO-DMT on pyramidal neuron activity
in mPFC
The effect of 5-MeO-DMT administration on pyramidal
discharge was examined in 37 rats (one neuron per rat)
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Fig. 2. Effect of 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) administration on blood-oxygen level dependent (BOLD) and
low frequency cortical oscillation (LFCO) responses. (A1) Representative coronal slices showing the region of interest (ROI)
analyzed. (A2) Bar graph showing the temporal effect of 5-MeO-DMT on BOLD signal in the different ROI: medial prefrontal cortex
(mPFC), primary and secondary somatosensory cortex (S1 and S2, respectively), primary and secondary visual cortex (V1 and V2,
respectively), auditory cortex (Au12), hippocampus (HPC), mediodorsal thalamus (MD), ventroposterior thalamus (VP) and nucleus
accumbens (NAc). In order to show the effect of 5-MeO-DMT on functional magnetic resonance imaging (fMRI) signal intensity
saline effect was subtracted from the effect of 5-MeO-DMT on the bar graph. *p<0.05 vs. saline. (b) Spectrograms showing the
effects of clorgyline and 5-MeO-DMT on LFCO in primary visual area (V1) and bar graph showing the averaged effects in mPFC
and V1. *p<0.05 vs. basal.
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pretreated with clorgyline. When considering the individ-
ual change from baseline, 5-MeO-DMT increased the
ﬁring rate of 51% of the neurons (to 406% of baseline),
reduced that of 35% (to 31% of baseline), and left the
rest (14%) unaffected (Fig. 1c). Overall, 5-MeO-DMT
increased pyramidal ﬁring rate to 215% of baseline (p<
0.001, Student’s t test; n=37). This was accompanied by
an increase in the number of burst episodes (from 15±2
to 37±8 in 2-min periods, p<0.01, Student’s <0.01 t test;
n=37).
Given the experimental design (drugs administered
5min after 5-MeO-DMT), we compared the effects of
5-MeO-DMT at 4th–5th and 9th–10th min post-
administration, in order to avoid confounding drug ef-
fects with spontaneous reversals after 5-MeO-DMT. A
group of rats was administered with saline 5min after
5-MeO-DMT. One-way repeated-measures ANOVA of
the ﬁring rate data revealed a signiﬁcant effect of the
treatment [F3,18 =10.2, p<0.0004, n=7] with signiﬁcant
post-hoc differences between 5-MeO-DMT and baseline
and non-signiﬁcant differences between the different
times post-administration (0.5±0.1, 0.5±0.2, 1.7±0.4,
2.8±0.7 spikes/s in basal conditions, after CLG, 5-MeO-
DMT and saline, respectively).
Effect of 5-MeO-DMT on LFCO oscillations
In parallel with the effect on pyramidal discharge, 5-MeO-
DMT signiﬁcantly reduced the amplitude of LFCO in
mPFC [F2,114=139.98; n=58, p<0.000001]. Power spectra
were 0.31±0.02, 0.31±0.02 and 0.20±0.01 μV2 during
basal, CLG and 5-MeO-DMT periods, respectively. This
effect was observed in all recordings, irrespectively of
whether 5-MeO-DMT enhanced, reduced or left unaffec-
ted the discharge rate of the pyramidal neuron recorded
simultaneously. Figure 1d shows a representative exam-
ple of LFP recording. One-way repeated measures
ANOVA revealed a signiﬁcant effect of 5-MeO-DMT at
min 4th–5th, 9th–10th and 14th–15th post-administration
[F4,12=8.59, p<0.002, n=4] with signiﬁcant post-hoc dif-
ferences between 5-MeO-DMT and baseline and no
signiﬁcant differences between 4th–5th, 9th–10th and
14th–15th min after 5-MeO-DMT administration.
Effect of 5-MeO-DMT on BOLD signal
5-MeO-DMT administration signiﬁcantly reduced the
BOLD signal in mPFC and V1. Two-way ANOVA of
the BOLD signal revealed a signiﬁcant effect of the drug×
time interaction in mPFC [F4,64=3.39; p<0.02] and V1
[F4,64=3.41; p<0.02] n=10 and 8 for saline and
5-MeO-DMT, respectively, with signiﬁcant post-hoc differ-
ences between 5-MeO-DMT and saline in all post-
treatment periods (Fig. 2).
Since hallucinogenic drugs are known to have clear
effects on the autonomic nervous system and blood press-
ure (McCall et al., 1987; McCall and Harris, 1988). In order
to examine whether fMRI changes had such an origin, we
assessed the effect of 5-MeO-DMT on arterial blood gas
levels in the same experimental conditions and the same
times acquisition than fMRI. A statistical comparison of
the paCO2 values using two-way ANOVA did not reveal
any signiﬁcant effect of treatment ([F1,7=3.07, n.s.] nor
treatment× time interaction [F4,28 =0.34, n.s,], n=4 and 5
for saline and 5-MeO-DMT treatment. Similarly, two-way
ANOVA revealed a non-signiﬁcant effect of 5-MeO-DMT
[F1,7 =0.1925; n.s.], and of the treatment× time interaction
[F4,28=1.09, n.s,], n=4 and 5 for saline and 5-MeO-DMT
on paO2 values (Table 1).
Effect of 5-MeO-DMT on V1 oscillations
Given the change in BOLD signal in V1, we performed
additional experiments to examine the effect of
5-MeO-DMT in this cortical area. Simultaneous record-
ings in mPFC and V1 indicated that 5-MeO-DMT admin-
istration concurrently reduced the amplitude of LFCO
similarly in both cortical areas (Fig. 2). Two-way
ANOVA revealed a signiﬁcant effect of 5-MeO-DMT
[F2,12=32.28; p<0.0001], for mPFC (n=4) and V1 (n=4),
with no signiﬁcant area differences nor treatment×area
interaction.
Antipsychotic drug reversal of 5-MeO-DMT-induced
alterations on mPFC activity
Next, we examined whether clozapine and haloperidol
could reverse the disruption of mPFC activity induced
Table 1. Mean group weights and arterial blood gases measurements. Abbreviations: PaCO2 – partial pressure of arterial CO2;
PaO2 – partial pressure of arterial O2; values were measured at the end of functional magnetic resonance imaging (fMRI) time series
([−5′–0′], [0′–5′], [5′–10′], [10′–15′], [15′–20′], respectively). Values expressed as mmHg and presented as mean±S.E.M; n=4 and 5 for saline
and 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) groups, respectively
Group Weight (g) paCO2 [0′] paCO2 [5′] paCO2 [10′] paCO2 [15′] paCO2 [20′]
SALINE 304±20 46±2 46±1 45±1 44±1 44±1
5-MeO-DMT 305±15 40±3 42±2 43±2 41±1 41±1
Group Weight (g) paO2 [0′] paO2 [5′] paO2 [10′] paO2 [15′] paO2 [20′]
SALINE 304±20 93±3 92±3 92±3 95±4 99±2
5-MeO-DMT 305±15 89±3 83±4 87±3 91±3 92±2
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by 5-MeO-DMT. Figure 3 shows an example of the con-
current effects of 5-MeO-DMT on pyramidal discharge
and LFCO and the normalization of both variables
induced by CLZ. One-way repeated-measures ANOVA
revealed a signiﬁcant effect of the treatment [F3,15 =
11.32, p<0.0005, n=6] on ﬁring rate. Post-hoc analysis
showed signiﬁcant differences between baseline and
5-MeO-DMT periods and between 5-MeO-DMT and
5-MeO-DMT+CLZ periods.
Similarly, HAL administration reversed the increase in
ﬁring rate induced by 5-MeO-DMT. One-way repeated-
measures ANOVA revealed a signiﬁcant effect of the
treatment [F3,18=4.39, p<0.02, n=7]. Post-hoc analysis
showed signiﬁcant differences between baseline and 5-
MeO-DMT periods and between 5-MeO-DMT and
5-MeO-DMT+HAL periods (Fig. 4a–c). Additionally,
both antipsychotic drugs reversed the increase in burst
episodes induced by 5-MeO-DMT (Fig. 4d).
In a subsequent set of experiments only involving
LFCO recordings, we conﬁrmed the ability of CLZ and
HAL to reverse 5-MeO-DMT effects on LFCO and exam-
ined whether risperidone (RIS) was also effective. The
three antipsychotic drugs reversed the reduction in
LFCO amplitude induced by 5-MeO-DMT. Two-way
ANOVA of the LFCO data revealed a signiﬁcant effect
of post-treatment (saline or antipsychotic drug) [F3,96 =
100.16; p<00001] and of group-by-post-treatment inter-
action [F9,96=9.24, p<0.0001], n=8, 11, 5, 12 for saline,
CLZ, RIS and HAL, respectively, with signiﬁcant post-hoc
differences between 5-MeO-DMT vs. 5-MeO-DMT+anti-
psychotic drug in all groups (Fig. 4e, f).
Involvement of 5-HT1A and 5-HT2A receptors in
5-MeO-DMT-induced effects
Given the in vitro afﬁnity of 5-MeO-DMT for 5-HT1A-R
and 5-HT2A-R receptors, we next examined which re-
ceptor(s) was(were) involved in the reduction of LFCO
amplitude. The selective 5-HT2A-R antagonist M100907
and the selective 5-HT1A-R antagonist WAY100635
CLZ
(1 mg/kg i.v.)(a)
(b)
20
10H
z
0
1
0LF
P
vo
lt
–1
5-MeO-DMT
(0.1 mg/kg i.v.)
0.12
40
30
20
S
pi
ke
/1
0s
10
0
0 10 Hz
µV
2
0.12
0 10 Hz
µV
2
0.12
0 10 Hz
1 min
µV
2
Fig. 3. Simultaneous single unit and low frequency cortical oscillation (LFCO) recordings showing the effect of 5-MeO-DMT
(5-Methoxy-N,N-dimethyltryptamine) and its reversal by clozapine (CLZ). Note the simultaneous effect of the hallucinogen and its
reversal by the antipsychotic on LFCO (a) and pyramidal discharge (b). Clorgyline was administered 15min prior 5-MeO-DMT
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were administered after 5-MeO-DMT using the same
treatment schedule than in previous experiments.
Both agents reversed the fall in LFCO induced by
5-MeO-DMT in mPFC (Fig. 5). Two-way ANOVA analy-
sis of the LFCO data revealed a signiﬁcant effect of
group-by-post-treatment interaction [F6,39=2.75, p<0.03,
n=8, 4, 4, for saline, M100907, and WAY100635 post-
treatment, respectively], with signiﬁcant post-hoc
differences between 5-MeO-DMT vs. baseline in all
groups.
When administered alone neither antagonists altered
the LFCO by itself (WAY100635: 102±2%, 103±7%, 107
±6% 108±6%, baseline-25–50–100 μg/kg i.v, respectively;
M100907: 100±2%, 94±11%, 83±10% 105±10%, baseline-
0.15–0.3–0.6 mg/kg i.v, respectively) (Fig. 6). One-way
repeated-measures ANOVA of the LFCO revealed no
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Fig. 4. Reversal by antipsychotic drugs of the effects of 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) on mPFC activity.
(a and b). Examples of two pyramidal neurons showing an increase in the discharge rate after 5-MeO-DMT administration, which
was reversed by the subsequent administration of clozapine (CLZ) (a) or haloperidol (b). (c) Bar graph showing the average effects
of clorgyline; clorgyline+5-MeO-DMT and its reversal by clozapine (n=6) and haloperidol (n=7) on pyramidal discharge. (d) Bar
graph showing the average effects of clorgyline; clorgyline+5-MeO-DMT and its reversal by clozapine (n=6) and haloperidol (n=7)
on mPFC pyramidal neuron burst discharge. (e) Spectrograms showing the effects of the administration of saline, haloperidol
(HAL), risperidone (RIS) and CLZ on 5-MeO-DMT-induced reduction on low frequency cortical oscillations (LFCO) (see doses in
the text). (f). Bar graph showing the average effects on LFCO of saline, (n=8); HAL (n=12); RIS, (n=5); and CLZ, (n=11). *p<0.01
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signiﬁcant effect of 5-HT1A -R antagonist WAY100635
(25–100 μg/kg i.v.) treatment [F3,9 =0.42, n.s. n=4] nor
5-HT2A-R antagonist M100907 (0.15–0.6 mg/kg i.v.) treat-
ment [F3,12 =1.73, n.s. n=5].
Reversal of 5-MeO-DMT-induced alterations on LFCO
by mGluR2/3 agonist
5-HT2A-R and mGluR2/3 have been shown to form func-
tional heterodimers that may be sensitive to the action of
hallucinogens (Gonzalez-Maeso et al., 2008). We therefore
examined whether the mGluR2/3 agonist LY-379268
could reverse the reduction in LFCO amplitude induced
by 5-MeO-DMT. Two-way ANOVA analysis of the
LFCO data revealed a signiﬁcant effect of group-by-post-
treatment interaction [F3,33=7.06, p<0.001, n=8 and 5 for
saline, and LY-379268 post-treatment, respectively], with
signiﬁcant post-hoc differences between 5-MeO-DMT vs.
baseline in all groups. Likewise, post-hoc test revealed
a signiﬁcant difference in the effect of saline and
LY-379268 administration (Fig. 5c, d).
When administered alone the mGluR2/3 agonist
LY-379268 induced a slight increase of LFCO (104±2%,
113±7%, 122±3%, 135±4%, baseline-0.5–1–2mg/kg i.v,
respectively). One-way repeated-measures ANOVA re-
vealed a signiﬁcant effect of the LY-3792668 (0.5–2mg/
kg i.v.) [F3,9 =10.16, p<0.003, n=4] on LFCO. Post-hoc
analysis showed signiﬁcant differences between baseline
and LY-379268 (1mg/kg) period or LY-379268 (2mg/kg)
period (Fig. 6).
Discussion
The present study shows that 5-MeO-DMT, in conditions
of MAO-A inhibition to mimic the effects of Ayahuasca,
markedly disrupted cortical activity. Few previous
studies examined the actions of 5-MeO-DMT on brain ac-
tivity. 5-MeO-DMT and other serotonergic hallucinogens
inhibited rat dorsal raphe cell ﬁring (de Montigny and
Aghajanian, 1977), whereas other studies reported elec-
troencephalography (EEG) alterations in humans taking
Ayahuasca (Riba et al., 2002, 2004). However, to our
knowledge, no previous study examined the effects
5-MeO-DMT on cortical activity. Here we show that
5-MeO-DMT altered the discharge rate of 86% of the
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recorded pyramidal neurons (51% excited, 35% inhibited)
and increased the number of burst episodes. The opposite
effects on neuronal discharge may result from the ac-
tivation of 5-HT2A-R in the recorded pyramidal neurons
or in adjacent GABAergic interneurons, respectively,
given the expression of 5-HT2A-R in both neuronal
types (Santana et al., 2004) and the involvement of
GABAergic interneurons in the inhibitory actions of
DOI (Puig et al., 2003; Wischhof and Koch, 2012).
In parallel to the individual changes in pyramidal
neuron activity, 5-MeO-DMT reduced LFCO. Cortical os-
cillatory activity is a critical part of brain function due to
its involvement in input selection, temporal coordination
of activity, and synaptic plasticity (Buzsaki and Draguhn,
2004). Alterations in oscillatory activity have been as-
sociated with schizophrenia (Winterer and Weinberger,
2004; Uhlhaas and Singer, 2006; Ferrarelli et al., 2007)
and the study of brain oscillations across frequencies
has been proposed as a translational tool in schizophrenia
research (Ford et al., 2007). Alterations in cortical os-
cillatory activity also occur in neurodevelopmental and
pharmacological models of schizophrenia (Goto and
Grace, 2006; Kargieman et al., 2007; Celada et al., 2008;
Santana et al., 2011). The cortically generated slow
oscillation (LFCO, ∼1 Hz) is a population variable that
reﬂects the spontaneous changes of membrane potential
in large neuronal ensembles during slow-wave sleep
and anesthesia (from depolarized or ‘up’ states to hyper-
polarized or ‘down’ states). LFCO group other brain
rhythms (Steriade, 2001, 2006), helping to establish tem-
poral patterns of cortical activity and cortical-subcortical
communication, as pyramidal neuron discharge occurs
mainly during active (or ‘up’) phases of LFCO. In parallel
with the effects on pyramidal discharge, 5-MeO-DMT
markedly reduced LFCO in mPFC and V1, an action po-
tentially related to its psychedelic activity. These altera-
tions are similar to those produced by PCP and DOI
(Kargieman et al., 2007, 2012; Celada et al., 2008; see
Celada et al., 2013 for review). Hence, in common with
these psychotomimetic agents (Fig. 7), 5-MeO-DMT
evoked a disrupted activity state characterized by
(1) altered pyramidal neuron discharge/pattern, and
(2) reduced intensity of LFCO. However, the effect size
was different for the three agents, begin more marked
for PCP (Kargieman et al., 2007), whereas DOI and
5-MeO-DMT evoked a smaller reduction (Celada et al.,
2008). These differences may be related to the distinct
psychotropic effects of PCP, DOI and 5-MeO-DMT.
5-MeO-DMT in conditions of MAO-A inhibition
evokes behavioral alterations in rodents that may be re-
lated to its psychedelic activity in humans (Halberstadt
et al., 2008; Halberstadt et al., 2012). Despite the present
observations have been obtained in anesthetized rats
they may also be related to these properties. Given the ex-
tensive projections of mPFC to many brain areas and the
top-down PFC control of their activity (Groenewegen and
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Uylings, 2000; Miller and Cohen, 2001; Gabbott et al.,
2005), the 5-MeO-DMT-evoked alterations in PFC activity
likely result in secondary activity changes in several
brain networks. Hence, pyramidal neurons expressing
5-HT2A-R project to midbrain monoaminergic nuclei
(Jakab and Goldman-Rakic, 1998; Vazquez-Borsetti et al.,
2009) which suggests downstream changes in mono-
aminergic activity. Additionally, 5-MeO-DMT-evoked
changes in V1 can contribute to the hallucinogenic
properties of Ayshuasca by altering nerve transmission
in this area and creating ‘false’ visual impressions
which would be subsequently processed by higher associ-
ation cortical areas, such as the PFC, whose function is
also altered by 5-MeO-DMT.
The present data are useful to understand the neuro-
biological basis of psychedelic action and suggest that
alterations in primary sensory areas (V1) and association
cortex (PFC) are involved. The relationship of the present
observations with schizophrenia symptoms is however,
less clear. A potential use of 5-MeO-DMT -in association
with CLG- as psychotomimetic agent is supported by
the similar changes evoked by 5-MeO-DMT and PCP
(Kargieman et al., 2007) and by the reversal of its actions
by marketed (CLZ, HAL, RIS) and potential (mGluR2/3
agonist) antipsychotic drugs. However, a main limitation
is the fact that 5-MeO-DMT altered the function of V1
whereas schizophrenic patients show essentially auditory
hallucinations. However, dysfunction across sensory sys-
tems and brain regions has been reported in schizo-
phrenic patients. Hence, early neuronal encoding of
visual stimuli in V1 is reduced in patients with schizo-
phrenia (Seymour et al., 2013). Moreover, impaired
efferent function in schizophrenia patients has been re-
ported in the auditory (Ford and Mathalon, 2012; Ford
et al., 2013) and visual systems (Spering et al., 2013),
probably contributing to the pathophysiology of the hal-
lucinations. Thus, 5-MeO-DMT, as well as other 5-HT2A
hallucinogens may be useful to elucidate brain areas/
networks involved in certain schizophrenia symptoms
but are unlikely to model the wide spectrum of psychotic
symptoms.
The above electrophysiological observations were par-
alleled by changes in BOLD signal in mPFC and V1. The
reduction in BOLD signal appears paradoxical, given the
overall increase in discharge produced by 5-MeO-DMT
and the relationship between neuronal discharge, energy
consumption and blood ﬂow. Early studies supported
an association between spiking activity and BOLD signal
(Boynton et al., 1996; Rees et al., 2000; Devor et al., 2003,
2005). However, other studies suggest a better correlation
with oscillatory than with spiking activity (Logothetis,
2003; Shmuel et al., 2006; Viswanathan and Freeman,
2007). Interestingly, a recent study in human volunteers
found negative BOLD signals in response to the psyche-
delic 5-HT2A-R agonist psilocybin, in agreement with
the present observations (Carhart-Harris et al., 2012).
Yet, despite these similarities, further work is required
to understand the relationship between BOLD signal
and neuronal activity.
5-MeO-DMT effects on LFCO were reversed by
the selective antagonists WAY-100635 and M100907,
which agrees with its in vitro afﬁnity for 5-HT1A-R and
5-HT2A-R (Sills et al., 1984; McKenna and Peroutka,
1989). This is also in agreement with behavioral studies
showing the involvement of 5-HT1A-R in the actions of
5-MeO-DMT (Winter et al., 1999, 2000; Krebs-Thomson
et al., 2006; van den Buuse et al., 2011). However, the
biphasic effect of 5-MeO-DMT (plus CLG, as in the pres-
ent study) on locomotor activity was antagonized by
5-HT2A-R- but not 5-HT1A-R-blockade (Halberstadt
et al., 2008), suggesting a distinct role of 5-HT1A-R in
the different experimental models used. The involvement
of 5-HT2A-R in the suppression of LFCO agrees with
a previous study (Celada et al., 2008), whereas that of
5-HT1A-R is still unclear. Thus, the preferential post-
synaptic 5-HT1A-R agonist F15599 did not alter LFCO
(Llado-Pelfort et al., 2010), while 8-OH-DPAT had a
biphasic effect by itself but reversed PCP effects
(Lladó-Pelfort et al., unpublished observations).
As previously observed with PCP and DOI
(Kargieman et al., 2007; Celada et al., 2008), the effects
of 5-MeO-DMT on neuronal ﬁring and LFCO were
reversed by HAL and CLZ (and RIS), acting mainly via
D2-R (HAL) and 5-HT2A-R blockade (CLZ, RIS) at the
doses used (Schotte et al., 1993). The reversal by CLZ
and RIS may result from the displacement of
5-MeO-DMT from 5-HT2A-R sites by the antipsychotics.
However, HAL effect must necessarily be interpreted by
changes of dopamine networks, given the negligible occu-
pancy of 5-HT2A-R at the dose used (Schotte et al., 1993).
Hence, ventral tegmental area stimulation excited fast-
spiking interneurons and inhibited pyramidal neurons
in mPFC, thus altering the excitatory/inhibitory balance
(Tseng et al., 2006). Likewise, dopamine D2-R stimulation
inhibits excitatory currents in mPFC pyramidal neurons
(Tseng and O’Donnell, 2007). Given the presence of dopa-
mine D2-R in pyramidal and GABAergic neurons
(Santana et al., 2009), HAL may normalize the altered
excitatory/inhibitory balance in mPFC, although further
work is required to clarify the exact mechanism.
Serotonergic and glutamatergic neurotransmission
play a signiﬁcant role in the pathophysiology and treat-
ment of schizophrenia (Marek and Aghajanian, 1998;
Marek et al., 2000; Miyamoto, et al., 2005; Moreno et al.,
2009). mGluR2/3 are potential new targets in schizo-
phrenia treatment (Patil et al., 2007) (although Eli Lilly re-
cently discontinued the development of the pro-drug
used in that clinical trial). A 5-HT2A-R/mGluR2 hetero-
dimers appear to be involved in psychosis and mediates
the psychedelic actions of serotonergic hallucinogens
(Gonzalez-Maeso et al., 2008; Moreno et al., 2011). Inter-
estingly, the antipsychotic-like activity of LY379268 re-
quires the expression of 5-HT2A-R (Fribourg et al., 2011).
The present results agree with this body of evidence,
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since the mGluR2/3 agonist LY379268 fully reversed the
effect of 5-MeO-DMT on LFCO, as observed for CLZ,
RIS and HAL. However, this effect might also derive
from functional interactions between both receptors,
given the modulatory role of 5-HT2A receptors. The re-
duction of excitatory inputs onto PFC pyramidal neurons
by LY379268 (Puig et al., 2003) may have altered 5-HT2A
receptor-mediated responses. However, despite pre-
synaptic 5-HT2A receptors have been postulated to me-
diate 5-HT2A-mGluR2/3 interactions (Marek et al., 2000),
their absence in glutamatergic axons of PFC (Miner
et al., 2003) suggests a post-synaptic location.
Together with previous ﬁndings, the present results
indicate that reductions in LFCO in PFC are a common
signature of psychotomimetics drugs. The reversal of
these effects by antipsychotic drugs with different
mechanisms of action suggests a clear association with
their therapeutic activity, regardless of their initial recep-
tor target (D2R; 5-HT2AR; mGluR2/3). This study further
supports the usefulness of the LFCO model in PFC to
examine the neurobiological basis of psychotic symptoms
(in particular, hallucinations) and offers new perspectives
to ﬁnd new targets in the treatment of hallucinations as
well as in antipsychotic drug development.
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